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UJIAN KERENTANAN UBAT TERHADAP Mycobacterium tuberculosis 
MENGGUNAKAN ASSAI MIKROPLAT TETRAZOLIUM (TEMA) LANGSUNG 
ABSTRAK 
Assai yang cepat, murah dan tinggi daya pemprosesan untuk ujian kerentanan ubat 
Mycobacterium tuberculosis (MTB) amat diperlukan terutamanya di negara-negara 
membangun yang mana kes batuk kering adalah berleluasa. Matlamat kajian ini 
adalah untuk menilai ujian kerentanan MTB terhadap ubat anti-TB barisan pertama 
dengan mengggunakan assai mikroplat tetrazolium (TEMA) langsung ke atas 
spesimen klinikal (kahak) tanpa keperluan untuk pemencilan MTB terlebih dahulu 
seperti yang biasanya dilakukan dalam TEMA tidak langsung. Sebanyak 59 sapuan 
spesimen kahak positif (AFB) telah dimasukkan secara langsung ke dalam kaldu 
media 7H9-S bebas ubat dan yang mengandungi pencairan bersiri ubat menggunakan 
pewarna tetrazolium sebagai petunjuk pertumbuhan dalam mikroplat. Semua 
kategori sapuan spesimen kahak positif (AFB) dengan bilangan berbeza (dari sedikit 
hingga 3+) telah digunakan dalam TEMA langsung manakala untuk TEMA tidak 
langsung, saiz inokulum piawai sebanyak 1.50 × 10
7
 CFU/mL  telah digunakan. 
Kepekatan perencat minima (MIC) untuk isoniazid (INH), rifampicin (RMP), 
ethambutol (EMB) dan streptomycin (SM) telah diperolehi dari TEMA langsung dan 
tidak langsung dengan merujuk kepada kaedah kepekatan mutlak (ACM). Lengkung 
(ROC) telah digunakan untuk menentukan nilai titik pemisah MIC. Sensitiviti, 
spesifisiti, kejituan, nilai ramalan dan juga tempoh keseluruhan pemprosesan untuk 
mendapatkan keputusan akhir ujian sensitiviti telah dibandingkan. Lebih daripada 
70% strain MTB mempunyai taburan MIC antara 0.0156 hingga 0.0313 µg/mL 
untuk INH; 0.0005 hingga 0.25 µg/mL untuk RMP; 0.5 hingga 2.0 µg/mL untuk 
EMB dan 0.0625 hingga 0.25 µg/mL untuk SM menggunakan TEMA tidak langsung 
 xiv 
manakala untuk TEMA langsung MIC bertaburan antara 0.0039 hingga 0.0625 
µg/mL untuk kedua-dua INH dan RMP; 0.25 hingga 1.0 µg/mL untuk EMB dan 
0.0625 hingga 0.25 µg/mL untuk SM. TEMA  langsung mempamerkan prestasi yang 
baik dengan secara tepat membezakan  strain MTB yang rintang dan rentan terhadap 
ubat anti-TB barisan pertama sepertimana yang diperlihatkan oleh  luas di bawah 
lengkungan (ROC) antara 0.7569 hingga 0.9643. Untuk TEMA tidak langsung, 
sensitiviti yang diperoleh masing-masing untuk INH, RMP, EMB dan SM adalah 
80%, 71%, 75% dan 100% manakala spesifisiti adalah 96%, 60%, 38% dan 84% 
masing-masing untuk INH, RMP, EMB dan SM. Untuk TEMA langsung pula, 
sensitiviti sebanyak 100% diperoleh untuk INH, EMB dan SM manakala 71% untuk 
RMP. Sebaliknya, spesifisiti untuk INH, RMP, EMB dan SM masing-masing adalah 
80%, 71%, 55% dan 93%. Secara keseluruhannya, kejituan dan nilai ramalan untuk 
TEMA langsung adalah setanding dengan TEMA tidak langsung. Tempoh 
pemprosesan keseluruhan 15 hari diperoleh dengan TEMA langsung diikuti dengan 
TEMA tidak langsung (39 hari) dan ACM (100 hari) (P < 0.001). Kesimpulannya, 
TEMA langsung adalah kaedah yang lebih mudah, cepat dan boleh dipercayai untuk 
ujian saringan kerentanan ubat MTB di negara-negara yang mempunyai peningkatan 
kadar prevalen strain ketahanan ubat. 
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DRUG SUSCEPTIBILITY TESTING OF Mycobacterium tuberculosis USING 
DIRECT TETRAZOLIUM MICROPLATE ASSAY (TEMA)   
ABSTRACT 
A rapid, inexpensive and high-throughput assay for drug susceptibility testing (DST) 
of Mycobacterium tuberculosis (MTB) is urgently required especially in developing 
countries where TB cases are prevalent. The aim of this study was to evaluate the 
drug susceptibility testing (DST) of MTB to the first-line anti-TB drug using 
tetrazolium microplate assay (direct TEMA) performed directly on clinical 
specimens (sputum) by omitting the need for prior isolation of MTB in sputum 
specimens currently performed by indirect TEMA. A total of 59 acid fast bacilli 
(AFB) smear positive sputum specimens were directly inoculated into drug-free and 
serially diluted drug in 7H9-S broth media using tetrazolium dye as growth indicator 
in the microplate wells. All AFB smear categories with different microscopic bacilli 
counts (from scanty to 3+) were included in the direct TEMA while the standard 
inoculum size used in the indirect TEMA was 1.50 × 10
7
 CFU/mL. The minimum 
inhibitory concentrations (MICs) of isoniazid (INH), rifampicin (RMP), ethambutol 
(EMB) and streptomycin (SM) were obtained for direct and indirect TEMA with 
reference to the absolute concentration method (ACM). Receiver Operating 
Characteristics (ROC) curve was used to determine the cut-off MIC values. The 
sensitivity, specificity, accuracy and predictive values as well as the mean turnaround 
time (TAT) for the final sensitivity test results were compared. The MIC for more 
than 70% of MTB strains were distributed between 0.0156 to 0.0313 µg/mL for INH; 
0.0005 to 0.25 µg/mL for RMP; 0.5 to 2.0 µg/mL for EMB and 0.0625 to 0.25 µg/mL 
for SM for indirect TEMA whereas 0.0039 to 0.0625 µg/mL for both INH and RMP; 
0.25 to 1.0 µg/mL for EMB and 0.0625 to 0.25 µg/mL for SM for direct TEMA. The 
 xvi 
direct TEMA method performed well by accurately distinguishing between the 
resistant and susceptible strains of MTB as seen by the area under the ROC curve 
(AUC) ranged from 0.7569 to 0.9643 against the first-line anti-TB drugs. In indirect 
TEMA, 80%, 71%, 75% and 100% sensitivities were obtained for INH, RMP, EMB 
and SM respectively while specificities were 96%, 60%, 38% and 84% for INH, 
RMP, EMB and SM respectively. In the direct TEMA, 100% sensitivity was 
obtained for INH, EMB and SM and 71% for RMP. However, the specificities for 
INH, RMP, EMB and SM were 80%, 71%, 55% and 93% respectively. The overall 
accuracy and predictive values of direct TEMA were comparable to indirect TEMA. 
A significant shorter mean TAT of 15 days was observed for direct TEMA followed 
by indirect TEMA (39 days) and ACM (100 days) (P < 0.001). In conclusion, direct 
TEMA is a relatively simple, rapid and reliable method for DST screening of MTB 
in countries with increasing prevalence rates of drug resistance strains.  
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CHAPTER 1 
INTRODUCTION 
1.1 Background of Study 
Mycobacterium tuberculosis (MTB) is an infectious agent responsible for 
tuberculosis (TB) among humans. In recent years TB has emerged as an important 
public health problem in both developing and developed countries (World Health 
Organization, 2013). The highest number of TB cases occurs among countries in 
South-East Asia and Western Pacific Regions which accounted for 56% of  cases 
worldwide in 2013 (World Health Organization, 2014). South-East Asia Region 
alone accounts for 33% of all cases globally (Vashishtha, 2009). The last ten years 
evidenced a steady increase in the number of TB cases in Malaysia from about 64 
cases per 100 000 population in 2003 (World Health Organization, 2009) to about 
72.4 cases per 100 000 population in 2011 (Ministry of Health Malaysia, 2011). 
According to 2014 World Health Organization (WHO) Report, the 
development of multi-drug resistant tuberculosis (MDR-TB) (MTB strain which is 
resistant to at least the two most powerful anti-TB drugs, INH and RMP) and the 
emergence of extensively drug resistant tuberculosis (XDR-TB) (MDR-TB that has 
developed resistance to any member of the fluoroquinolone family and at least one of 
the three injectable second-line anti-TB drugs: amikacin, kanamycin or capreomycin 
used to treat MDR-TB) posed a major obstacle in the treatment and control of TB 
worldwide. An estimated 480 000 MDR-TB cases were reported worldwide with 
resistance to anti-TB drugs varied from one country to another and in different 
regions within the same country (Zignol et al., 2006; World Health Organization, 
2008; World Health Organization, 2014).  
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A study done in Malaysia in the late 80’s reported that the rate of primary 
resistance to any type of first-line anti-TB drug was 13 – 15% while multi-drug 
resistant was about 1% (Jalleh et al., 1993). Another source indicated the prevalence 
of MDR-TB in Malaysia in 1997 was 0.1% (World Health Organization, 2000). A 
2012 statistics has estimated the cases of MDR-TB among notified TB cases in 
Malaysia at 18 cases (World Health Organization, 2013). Although few studies and 
statistic put forth to explain the prevalence rate in Malaysia, the systematic data on 
the prevalence of drug resistant TB (DR-TB) in the Peninsular Malaysia is still not 
available. The possible reasons for the paucity of information on MTB resistant 
pattern may be due to the lack of a simple, quick and affordable technique in 
determining the antibiotic susceptibility in most of the laboratories. 
1.2 Rationale of The Study 
The availability of a rapid, simple and inexpensive method for drug susceptibility 
testing (DST) would be very helpful for resources limited laboratories where TB is 
highly prevalent. Minimum inhibitory concentration (MIC) determination is very 
crucial in order to monitor susceptibility of MTB as well as to prevent transmission 
of MDR-TB in the community (Mshana et al., 1998). The present available methods 
for DST such as the gold standard: absolute concentration method (ACM) and 
proportion method (PM); automated methods: Radiometric BACTEC 460TB System 
and BACTEC Mycobacteria Growth Indicator Tube (MGIT) 960 System; E-test and 
new molecular tools seem to be time consuming and expensive for use in the 
underprivileged settings i.e., low income countries (Franzblau et al., 1998).  
Promising results were reported by several studies regarding the simple, low 
cost and rapid colorimetric assays that could be produced in house for determining 
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DST of MTB by the use of reagents such as Alamar blue (Yajko et al., 1995; 
Franzblau et al., 1998), dimethylthiazol-diphenyltetrazolium bromide (MTT) 
(Gomez-Flores et al., 1995) and 2,3,5-triphenyltetrazolium chloride (TTC) 
(Mohammadzadeh et al., 2006). The use of TEMA only costs USD 5.04 for each 
tested strain (Caviedes et al., 2002) compared to BACTEC 12B (USD 6.40) and 
MGIT (USD 12.00) (Heifets and Cangelosi, 1999). In addition, such colorimetric 
assays are able to handle multiple samples at a time (Franzblau et al., 1998). Besides, 
this method can produce high level of specificity and sensitivity in testing the 
susceptibility of MTB to the first-line anti-TB drugs (Gomez-Flores et al., 1995; 
Franzblau et al., 1998; Caviedes et al., 2002; Palomino et al., 2002; De Logu et al., 
2003; Morcillo et al., 2004; Martin et al., 2005; Mohammadzadeh et al., 2006). 
However, the assay described above uses pure culture from the clinical 
samples. This will not be able to reduce the total turnaround time for the final 
sensitivity result because it needs initial isolation of the organisms from samples by 
inoculation onto the Lowenstein-Jensen (L-J) medium for 3 to 4 weeks (Mshana et 
al., 1998). With that in mind, the colorimetric result could be made available 
relatively faster by direct inoculation of clinical sample using colorimetric assay for 
determination of drug susceptibility without initial isolation of MTB.  
Cognizant to the above limitation, this study aims to evaluate the performance 
of tetrazolium microplate assay (TEMA) for the determination of susceptibility of 
MTB to first-line anti-TB drugs directly from clinical samples (sputum) (direct 
TEMA) with comparison to the indirect TEMA (using pure culture isolate) and the 
gold standard method, ACM. 
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1.3 Objectives of The Study 
1.3.1 General Objective 
To evaluate the drug susceptibility testing (DST) of MTB to the first-line 
anti-TB drugs using TEMA performed directly on clinical specimens 
(sputum). 
1.3.2 Specific Objectives 
1. To determine the MIC of isoniazid (INH), rifampicin (RMP), ethambutol 
(EMB) and streptomycin (SM) by indirect TEMA on MTB pure culture 
isolate. 
2. To determine the MIC of INH, RMP, EMB and SM by direct TEMA on AFB 
smear positive sputum specimens. 
3. To determine the sensitivity, specificity, accuracy and predictive values of 
direct TEMA and indirect TEMA in comparison to the ACM as gold 
standard.  
4. To compare the total turnaround time (TAT) between the direct TEMA, 
indirect TEMA and ACM. 
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1.4 Study Framework 
 
Phase 1: Optimization of TEMA 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1:  The flow chart on the optimization of TEMA 
 
 
 
 
 
 
Culture of reference strain of MTB (H37Rv) onto Ogawa 
media  
 
Processing of samples for 
direct TEMA 
Spike into AFB negative sputum samples 
Inoculum size, drug concentration range 
and TAT determination and proceed to 
Phase 2 
Indirect sensitivity test 
against isoniazid, rifampicin, 
streptomycin and ethambutol 
by TEMA 
Direct sensitivity test against 
isoniazid, rifampicin, 
streptomycin and ethambutol 
by TEMA 
H37Rv culture preparation 
for indirect TEMA 
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Phase 2: Evaluation of TEMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2:  The flow chart on the evaluation of TEMA 
 
Collection of archived AFB positive sputum samples  
Processing of samples for direct TEMA 
and MTB culture preparation for indirect 
TEMA 
Direct susceptibility test against isoniazid, 
rifampicin, streptomycin and ethambutol 
by TEMA on sputum specimen (PPSP 
Lab) 
Culture onto 
Ogawa media 
for isolation of 
MTB (PPSP 
Lab) 
Analysis of data and report writing 
Indirect sensitivity test against isoniazid, 
rifampicin, streptomycin and ethambutol 
by TEMA on the pure culture (PPSP Lab) 
Send the isolate to National Public Health 
Laboratory, Sungai Buloh for: 
 i. Identification by molecular method  
ii. DST by ACM 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Mycobacterium tuberculosis (MTB)  
The genus Mycobacterium comes from the family Mycobacteriaceae which is the 
only genus in this family. MTB and M. leprae are two very important human 
pathogens and respectively cause TB and leprosy whereas the non-tuberculos 
mycobacteria (NTM) are associated with various kinds of mycobacterioses in 
humans and animals (Goodwin, 2007; Pfyffer and Palicova, 2011). 
Mycobacteria were previously classified based on their phenotypic 
characteristics which comprise growth rates, photo-reactivity, nutritional and 
environmental temperature requirements, biochemical test and the range of 
pathogenicity. Currently, classifications of mycobacteria are done by molecular-
based techniques using species-specific rRNA and DNA sequences (Goodwin, 2007; 
Ryan et al., 2010; Pfyffer and Palicova, 2011).  
MTB is slightly curved or straight slim single or branched bacilli, non-motile, 
0.2 to 0.6 µm by 1.0 to 10 µm in dimension and possesses acid-fast properties which 
stained poorly with Gram staining. Its cell wall contains peptidoglycan attached with 
many branched-chain polysaccharides, proteins and lipids (Goodwin, 2007; Ryan et 
al., 2010; Pfyffer and Palicova, 2011). 
Generally, mycobacteria are aerobic but some species can grow under reduced 
O2 atmosphere. MTB grows at optimum temperature of 37ºC and growth 
enhancement can be observed in the presence of 10% CO2 and at low pH (6.5 – 6.8). 
MTB have a slow growth rate and takes about 4 to 6 weeks to observe colonies 
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growing on solid media.  The presence of ammonia or amino acid as nitrogen sources 
and glycerol as a carbon source in addition to mineral salts are required for the 
growth of most MTB strains. The growth is also stimulated by fatty acid from egg 
yolk or oleic acid as well as albumin to neutralize the toxicity of excess fatty acid. 
The MTB colonies are rough and often appear as prominent patterned texture 
‘cording’ resulting from the tight cohesion of the bacilli (Goodwin, 2007; Ryan et 
al., 2010; Pfyffer and Palicova, 2011).  
Mycobacterial species can be identified by a set of biochemical tests based on 
the enzymes the organism possesses, metabolic substances and inhibition of growth 
on exposure to selected biochemical reagents. The set of biochemical tests include 
niacin accumulation, nitrate reduction, catalase reaction, hydrolysis of Tween-80, 
iron uptake, arylsulfatase, pyrazinamidase, tellurite reduction and urease test 
(Goodwin, 2007). Table 2.1 shows biochemical properties of mycobacteria. 
MTB complex is commonly isolated from patients suspected with TB. It is 
characterized by different phenotypes and mammalian host ranges with extreme 
genetic homogeneity. MTB complex comprises of several mycobacterial species 
including MTB, M. bovis, M. bovis BCG, M. africanum, M. caprae, M. microti, M. 
cenettii and M. pinnipedii (Pfyffer and Palicova, 2011). Table 2.2 describes the 
details of each member in MTB complex. 
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Table 2.1: Biochemical properties of mycobacterial species 
Test Organism detected Interpretation 
Niacin accumulation MTB Yellow-pigmented compound 
Nitrate reduction MTB, M. kansasii, M. szulgai and M. fortuitum Forming red colour 
Catalase MTB complex Heat-stable catalase negative 
Hydrolysis of Tween-80 Scotochromogenic mycobacteria Observing pink color change 
Iron uptake M. chelonae Rusty brown colonies 
Arylsulfatase enzyme Most mycobacterial species Pink colour 
Pyrazinamidase M. marinum, M. kansasii and M. bovis  Red pigment 
Tellurite reduction M. avium complex (MAC) Colourless to black 
Urease M. scrofulaceum  Pink to red 
Source: Goodwin (2007) 
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Table 2.2: Members of MTB complex: source and characteristics 
Organisms Host/Source Main characteristics 
M. tuberculosis Humans Off-white and rough in solid media, smoother in moist media 
M. bovis Warm-blooded animals, some prey birds and humans Small and rounded colonies with irregular edges and granular 
surface 
M. bovis BCG Vaccine Predominantly same properties of M. bovis except more 
attenuated in virulence 
M. africanum Humans in tropical Africa Colonies are the same as MTB in solid media 
M. caprae Goats and cattle In genomic view, M. caprae is identical to the branches of 
classical M. bovis, M. pinnipedii, M. microti and ancestral 
MTB but different from modern MTB 
M. microti Guinea pigs, rabbits, llamas, cats and other warm-blooded 
animals 
Appear as ‘croissant’-like morphology in stained smears, no 
growth in culture 
M. cenettii Child and HIV-positive patients Smooth, round and glossy colonies in solid media 
M. pinnipedii Guinea pigs, rabbits and possible cattle New member of the MTB complex by host preference, 
phenotypic and genotypic characteristics 
Source: Pfyffer and Palicova (2011)
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2.2 Pathogenesis and Clinical Features of Tuberculosis (TB) 
TB is an infectious disease that can affect human and animal, where MTB is the 
major etiologic agent. All members belong to the MTB complex cause TB infections 
(Ryan et al., 2010).  
TB infection begins when airborne droplet nuclei containing MTB enter the 
respiratory tract by means of inhalation. In the lobes, MTB cells are recognized and 
phagocytized by alveolar macrophages which undergo lysosomal mechanisms and T-
cell response. The T-cell then forms major histocompatibility complex (MHC) 
molecules. This will lead to cytokine activation (Goodwin, 2007; Ryan et al., 2010; 
Todar, 2012). 
Besides that, MTB multiplication will generate large quantity of MTB protein 
which can trigger inflammatory elements of delayed-type hypersensitivity (DTH) 
response (Kobayashi et al., 2001). The DTH with its component causes destruction 
and injury to cells containing antigen (Goodwin, 2007; Ryan et al., 2010). 
Hypersensitivity reaction results in the formation of granuloma. Healing occurs 
after granuloma formation along with fibrosis, encapsulation and scar formation. 
Primary infection may heal and the organisms will slowly dying. However, the 
bacilli may not be totally eradicated but can remain visible for months to years in 
granulomas and potentially produce reactivation TB later if the cellular immune 
system of the infected persons is altered or suppressed due to aging, malnutrition, 
alcoholism, immunosuppressive treatment and AIDS. In this stage, apical or 
posterior segment of the upper lobe or superior segment of the middle lobe of the 
lung is commonly involved (Goodwin, 2007; Ryan et al., 2010). 
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TB infected individual is either asymptomatic or having signs and symptoms of 
TB disease or may be in extremely debilitated state depending on the stages of 
infection. Early clinical manifestations are often nonspecific such as malaise and 
fever. The chest X-ray may show infiltrates in the mid-zones of the lung and also 
adenopathy, an enlargement of lymph node around the hilum. Ghon’s complex 
characteristic is also present in the X-ray when enlarged lymph nodes fibrosed, 
combined with calcifications or scars on the middle lobe of lung (Ryan et al., 2010; 
Swierzewski, 2011).  
In active TB, a cough eventually develops in most patients which initially of 
nonproductive type and later advances to a productive cough with or without blood-
stained sputum. Several symptoms such as fever, breathlessness, malaise, fatigue, 
night sweats, weight loss and signs of pneumonia are also common. The chest X-ray 
shows the appearance of cavities in lung apices resulting from progressive 
destruction of lung tissue. The involvement of other organs such as bones, bone 
marrow, kidneys, lymph nodes, bowel, brain and meninges may occur at this stage. 
Infected organs manifest with tuberculoma, localized tumor-like mass that is not a 
cancer and fatal chronic meningitis. Untreated TB patient with progressive cough, 
fever and weight loss would develop complications such as empyema, pleural 
fibrosis, massive hemoptysis, adrenal insufficiency, hypercalcemia and if prolong 
within 2 to 5 years can cause death (Ryan et al., 2010).  
2.3 Epidemiology of TB 
Humans are the only reservoir of MTB. Most TB infections are transmitted via 
inhalation of droplet nuclei containing the causative organism.  In the situation of 
poor ventilation, the risk of inhaling the infected droplet nuclei is increasing. Besides 
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that, TB can also be transmitted through the gastrointestinal tract. It occurs after 
individual consuming fresh milk directly from TB cattle. However, this mode of 
transmission is uncommon due to pasteurization of milk (Ryan et al., 2010; Todar, 
2012). 
2.3.1 Global TB Burden 
TB is still a major public health problem worldwide both in developing and 
developed countries and the second leading cause of death in categories of infectious 
diseases after the HIV. It has been reported that about 9 million incident cases of TB 
were estimated worldwide in 2013 (World Health Organization, 2014). Asia 
contributed the highest number of cases (about 56%), followed by 29% in Africa, 8% 
in Eastern Mediterranean Region, 4% in European Region and about 3% in the 
Region of Americas. India contributed the highest numbers of cases with 2.0 – 2.3 
million people infected (about 26% of global cases) followed by China (0.9 – 1.1 
million cases), Nigeria (340 000 – 880 000 cases), Pakistan (370 000 – 650 000 
cases), Indonesia (410 000 – 520 000 cases) and South Africa (410 000 – 520 000 
cases) in 2013. About 11 – 14% of TB cases notified in 2013 were among HIV 
infected patients. The highest incidence rates of TB co-infected with HIV cases were 
seen in Africa Region in 2013 (World Health Organization, 2014). TB prevalent 
cases were estimated about 10 – 13 million which equivalent to 159 cases per 100 
000 population in 2013. An estimated 1.5 million TB deaths in 2013 among which 
73% were HIV-negative and 24% were HIV-positive. Africa and South-East Asia 
Regions accounted for approximately 78% of total TB deaths globally whereas one-
third of these occurred in India and Nigeria alone in 2013 (World Health 
Organization, 2014). Figure 2.1 shows the estimated percentage of TB incident cases 
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and mortality rates in 2013 by world region whereas Figure 2.2 shows world map 
distribution of estimated TB incidence rates in 2013.   
2.3.2 TB in Malaysia 
Although TB is still a major public health disease in Malaysia, its epidemiological 
data has not been regularly updated. The rate of TB cases in Malaysia was about 72.4 
cases per 100 000 populations in 2011 (Ministry of Health Malaysia, 2011). A total 
of 15 057 cases of all forms of TB were notified in 2000 (Iyawoo, 2004), increased 
about 1 – 7% annually until 2010 (Ministry of Health Malaysia, 2010) and in 2011 
about 20 666 cases were notified. The state of Sabah accounted for the highest 
number of TB cases (Dony et al., 2004; Iyawoo, 2004). Factors such as low social-
economic and also the high number of immigrant population were associated with 
increasing TB cases detected in Sabah (Dony et al., 2004). This finding was 
supported by molecular detection of foreign TB strains among local TB infected 
patients (Dale et al., 1999). Other factors include rapid urbanization, crowding, dirty 
environment and malnutrition (Ibrahim, 2010). Among notified cases in 2011, about 
61.8% was smear positive cases, 23.5% was smear negative/not known/not done and 
14.7% was from extrapulmonary TB cases. There were about 1 644 TB deaths in 
2011 giving about 5.8 TB deaths per 100 000 population. Case detection rate and 
cure rate were 84.1% and 79% respectively in 2011 (Ministry of Health Malaysia, 
2011). Figure 2.3 shows decreasing trend of prevalence and incidence rates of TB 
from 2010 to 2012 in Malaysia. However, the mortality rate was constant throughout 
the period. 
 
 
 15 
Africa
38%
Europe
5%
Eastern 
Mediterranean
16%
The Americas
4%
South-East Asia
25%
Western Pacific
12%
A
Africa
42%
Europe
4%
Eastern 
Mediterranean
23%
The Americas
2%
South-East Asia
23%
Western 
Pacific
6%
B
 
Figure 2.1: World region estimated percentage of A: TB incidence and B: TB 
mortality rates in 2013 [adapted from World Health Organization (2014)] 
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Figure 2.2: World estimated TB incidence rates in 2013 [adapted from World Health Organization (2014)] 
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Figure 2.3: Estimated burden of disease caused by TB in Malaysia, 2010 – 2012 
[adapted from World Health Organization (2013)] 
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2.4 Diagnosis of TB 
The diagnosis of TB is mainly based on clinical symptoms, radiological finding 
(chest X-ray) and bacteriological evidence. The laboratory investigations are 
necessary to diagnose TB and to confirm susceptibility prior to TB drug treatment.  
2.4.1 Acid-Fast Stain and Microscopic Examination 
Detection of MTB can be performed routinely in laboratory by acid-fast stain 
method. Stained bacilli are detected microscopically in various clinical specimens 
such as sputum, cerebrospinal fluid (CSF) and others. There are variations of acid-
fast staining techniques. In the Ziehl-Neelsen stain (Z-N stain) procedure, AFB is 
detected as bright red against a blue background. Other method is the fluorescent 
acid-fast stain where AFB appears as luminescent yellow-green against a dark 
background (Ryan et al., 2010; Talaro and Chess, 2011). Recently there are 
recommendations to use the fluorescent light emitting diode (LED) microscope 
which gives more advantages (Wilson, 2011).  
2.4.2 Isolation and Identification of MTB 
Culture is the gold standard diagnostic tool for TB infection in which the causative 
agent can be isolated and identified as well as used for antimicrobial susceptibility 
testing. Culture method usually takes longer time about 3 to 4 weeks to show visible 
colonies on L-J or Ogawa media. However, detection of MTB must be accomplished 
as rapidly as possible before treatment can be initiated and also to avoid transmission 
of MTB to other people. As a result, several newer culture methods have been 
proposed which shorten the time to get the results including radiometric procedures 
such as BACTEC 460 TB system and fluorescent based detection such as BACTEC 
MGIT 960 system. Methods using DNA probes are also available to detect specific 
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genetic markers for identification of mycobacteria isolated in the culture (Ryan et al., 
2010; Talaro and Chess, 2011).  
2.4.3 Tuberculin Skin Test 
This test also called Mantoux test which has been used to measure the DTH. The test 
uses purified protein derivative (PPD), a standardized solution of TB protein 
preparation derived from culture fluids of MTB. A positive Mantoux test denotes 
prior antigenic exposure and the development of DTH due to MTB infection at some 
time. However this test cannot distinguish between active and latent TB infection 
(Ryan et al., 2010; Talaro and Chess, 2011).  
2.4.4 Nucleic Acid Amplification 
Nucleic acid amplification is a molecular technique that uses polymerase chain 
reaction (PCR) to detect MTB in clinical specimens. Commercially available kit with 
Food and Drug Administration (FDA) approval is the Amplicor Mycobacterium 
tuberculosis test by Roche Diagnostic Systems, Germany. The kit utilizes PCR to 
detect MTB directly in respiratory specimens. Another commercially available 
nucleic acid probe is AccuProbe manufactured by GenProbe, USA. The sensitivity of 
the assay is 95% to 100% (Forbes, 1995; Forbes et al., 2002; Goodwin, 2007).  
Furthermore, there is a newly developed technology known as loop-mediated 
isothermal amplification (LAMP) which is more simple, rapid and sensitive 
(Iwamoto et al., 2003). Overall, nucleic acid amplification is rapid compared to other 
method such as culture method (Moore et al., 2005).  
 
 
 20 
2.4.5 Immunodiagnostic Tests 
The serological test is another type of immunodiagnostic technique. A test kit called 
Quantiferon-TB Gold kit was developed (Cellestis Limited, Australia). The test 
measures the cell-mediated immune response in blood samples to mycobacterial 
antigens which is then measured using Quantiferon-TB Gold ELISA technique. The 
technique is more effective due to less affected by BCG vaccination and cross-
reactivity with other antigens (Goodwin, 2007). 
2.5 Treatment by Anti-TB Drugs 
Anti-TB drugs generally kill the bacilli in the lungs, organs as well as macrophages. 
There are several anti-TB drugs for treating TB patients. The primary drug of choice 
also called first-line anti-TB drugs which include isoniazid (INH), rifampicin (RMP), 
ethambutol (EMB), streptomycin (SM) and pyrazinamide (PZA) are used in 
combination to treat the patients infected with susceptible MTB. These drugs have 
been widely used with long clinical experience, good efficacy and known side 
effects.  Besides that, there are also second-line anti-TB drugs which less preferred 
and act as back up or reserve for use in patients who fail to respond to first-line anti-
TB drugs. The drugs include para-Aminosalicylic acid (PAS), ethionamide, 
cycloserine, fluoroquinolones and kanamycin (Ryan et al., 2010; Talaro and Chess, 
2011).  
The TB patients are usually treated with multiple drugs consisting of two to 
four types of drugs. Usually for the new TB patients, combinations of four first-line 
drugs are empirically administered while waiting for drug susceptibility test (DST) 
results (Ryan et al., 2010; Talaro and Chess, 2011). In Malaysia, according to 
Clinical Practice Guideline in Management of Tuberculosis (2012), new pulmonary 
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TB patients will receive treatment of two months combination of INH, RMP, EMB 
and PZA followed by four months combination of INH and RMP. Second-line anti-
TB drugs are used when treatment failure or resistance detected toward first-line 
drugs. The patients will be treated according to standard MDR-TB regimen. The 
regimen contains fluoroquinolone, ethionamide, four second-line anti-TB drugs and 
PZA in the intensive phase (Malaysia Health Technology Assessment Section, 
2012). Table 2.3 summarizes the first-line anti-TB drugs used for TB treatment.  
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Table 2.3: Summary of the first-line anti-TB drugs used for TB treatment  
Drugs Properties Admission 
Mode of 
action 
Resistant Side effect 
INH Colourless, 
water soluble 
and small 
molecule 
Oral Lose the 
MTB acid-
fastness 
Mutation 
in katG 
and inhA 
genes 
Nervous systems 
and liver 
damage 
RMP Semisynthetic 
product and 
lipid soluble 
Oral Prevent 
MTB 
mRNA 
synthesis 
Mutation 
in rpoB 
gene 
Hypersensitivity 
and liver 
damage 
EMB Synthetic 
compound 
Oral Inhibit 
formation 
of MTB 
cell wall 
Mutation 
in 
embCAB 
genes 
Optic neuritis 
SM Structure 
composes of 
amino sugar 
IM Inhibit 
MTB 
protein 
synthesis 
Mutation 
in rrs and 
rpsL genes 
Nephrotoxicity 
PZA Analog to 
nicotinamide 
Oral Cause 
MTB non-
specific 
damage 
Mutation 
in pncA 
gene 
Liver toxic 
IM, intramuscular injection 
Source: Rom and Garay (2004); Donald and Mcllleron (2009) 
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2.6 Drug Resistant Tuberculosis (DR-TB) 
2.6.1 Multidrug-Resistant Tuberculosis (MDR-TB) 
MDR-TB is caused by MTB strain which is resistant to at least the two most 
powerful anti-TB drugs, INH and RMP. The emergence of MDR-TB has become a 
serious problem as a result of global misuse of INH and RMP thus rendering 
difficulties in the treatment and control of TB (U.S. Department of Health and 
Human Services, 2012). Global estimation of new TB cases with MDR-TB is 3.5% 
whereas 20.5% were estimated from previously treated TB cases in 2013 (World 
Health Organization, 2014). The Eastern Europe and Central Asia had the highest 
levels of MDR-TB with estimated 450 000 new cases of MDR-TB worldwide and 
about 300 000 MDR-TB cases were among notified TB patients in 2012 (World 
Health Organization, 2013).  
In Malaysia, a study in the late 80’s reported that the rate of primary resistance 
to any type of first-line anti-TB drugs was 13 – 15% whereas about 1% was MDR-
TB cases (Jalleh et al., 1993). The prevalence of MDR-TB was 0.1% in 1997 
(Iyawoo, 2004). The WHO 2013 report stated that total laboratory confirmed MDR-
TB cases in Malaysia was 74 cases and the estimated cases of MDR-TB among 
notified pulmonary TB was 18 cases in 2012 (World Health Organization, 2013). 
Figure 2.4 shows estimated notified cases of MDR-TB by world region in 2012 and 
numbers of confirmed MDR-TB cases in Malaysia from 2005 to 2012. 
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Figure 2.4: A: World region estimated notified cases of MDR-TB in 2012 and B: 
Number of confirmed cases of MDR-TB in Malaysia, 2005– 2012 [adapted from 
World Health Organisation (2010) and (2013)] 
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